Mobile

A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-000452-24

A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To: - Assess the durability of response for subjects who achieved SVR12 with a regimen including ABT-493 and/or ABT-530. - Assess the emergence and persistence of specific HCV amino acid variants associated with drug resistance in subjects who experience virologic failure.

Critère d'inclusion

  • HEPATITIS C VIRUS

Liens